TG Therapeutics Inc has a consensus price target of $20.82, established from looking at the 50 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Ladenburg Thalmann, and HC Wainwright & Co. on May 2, 2024, May 2, 2024, and April 18, 2024. With an average price target of $44.67 between HC Wainwright & Co., Ladenburg Thalmann, and HC Wainwright & Co., there's an implied 170.05% upside for TG Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/02/2024 | Buy Now | 196.25% | HC Wainwright & Co. | Edward White | $45 → $49 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | 141.84% | Ladenburg Thalmann | Matthew Kaplan | $39 → $40 | Maintains | Buy | Get Alert |
04/18/2024 | Buy Now | 172.07% | HC Wainwright & Co. | Edward White | → $45 | Reiterates | Buy → Buy | Get Alert |
04/18/2024 | Buy Now | 51.15% | JP Morgan | Eric Joseph | → $25 | Reiterates | Overweight → Overweight | Get Alert |
04/18/2024 | Buy Now | 135.79% | Ladenburg Thalmann | Matthew Kaplan | → $39 | Reiterates | Buy → Buy | Get Alert |
03/01/2024 | Buy Now | 172.07% | HC Wainwright & Co. | Edward White | → $45 | Reiterates | Buy → Buy | Get Alert |
02/29/2024 | Buy Now | -21.4% | Goldman Sachs | Corinne Jenkins | $12 → $13 | Maintains | Neutral | Get Alert |
02/28/2024 | Buy Now | 172.07% | HC Wainwright & Co. | Edward White | → $45 | Reiterates | Buy → Buy | Get Alert |
02/05/2024 | Buy Now | 75.33% | B. Riley Securities | Mayank Mamtani | $24 → $29 | Maintains | Buy | Get Alert |
01/11/2024 | Buy Now | 172.07% | HC Wainwright & Co. | Edward White | $41 → $45 | Maintains | Buy | Get Alert |
11/01/2023 | Buy Now | — | Jefferies | Matthew Andrews | — | Maintains | Buy | Get Alert |
11/01/2023 | Buy Now | 39.06% | JP Morgan | Eric Joseph | $22 → $23 | Maintains | Overweight | Get Alert |
10/20/2023 | Buy Now | 45.1% | B. Riley Securities | Mayank Mamtani | $32 → $24 | Maintains | Buy | Get Alert |
09/18/2023 | Buy Now | 147.88% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
08/07/2023 | Buy Now | 33.01% | JP Morgan | Eric Joseph | $34 → $22 | Maintains | Overweight | Get Alert |
08/03/2023 | Buy Now | -27.45% | Goldman Sachs | Corinne Jenkins | $16 → $12 | Maintains | Neutral | Get Alert |
08/02/2023 | Buy Now | 93.47% | B. Riley Securities | Mayank Mamtani | $42 → $32 | Maintains | Buy | Get Alert |
08/02/2023 | Buy Now | -27.45% | Goldman Sachs | Corinne Jenkins | $16 → $12 | Upgrade | Sell → Neutral | Get Alert |
08/01/2023 | Buy Now | 93.47% | B. Riley Securities | Mayank Mamtani | $42 → $32 | Reiterates | Buy → Buy | Get Alert |
08/01/2023 | Buy Now | 147.88% | HC Wainwright & Co. | Edward White | $34 → $41 | Maintains | Buy | Get Alert |
07/25/2023 | Buy Now | -3.26% | Goldman Sachs | Corinne Jenkins | $10 → $16 | Maintains | Sell | Get Alert |
07/24/2023 | Buy Now | -3.26% | Goldman Sachs | Corinne Jenkins | $10 → $16 | Maintains | Sell | Get Alert |
07/13/2023 | Buy Now | 153.93% | B. Riley Securities | Mayank Mamtani | → $42 | Reiterates | Buy → Buy | Get Alert |
06/01/2023 | Buy Now | 105.56% | HC Wainwright & Co. | Edward White | → $34 | Reiterates | → Buy | Get Alert |
05/31/2023 | Buy Now | 105.56% | HC Wainwright & Co. | Edward White | → $34 | Reiterates | → Buy | Get Alert |
05/02/2023 | Buy Now | 126.72% | Ladenburg Thalmann | Matthew Kaplan | $26 → $37.5 | Maintains | Buy | Get Alert |
05/01/2023 | Buy Now | 105.56% | HC Wainwright & Co. | Edward White | $28 → $34 | Reiterates | → Buy | Get Alert |
04/17/2023 | Buy Now | 45.1% | Cantor Fitzgerald | Prakhar Agrawal | → $24 | Reiterates | → Overweight | Get Alert |
04/14/2023 | Buy Now | 69.29% | HC Wainwright & Co. | Edward White | $24 → $28 | Reiterates | → Buy | Get Alert |
03/31/2023 | Buy Now | 45.1% | HC Wainwright & Co. | Edward White | → $24 | Reiterates | → Buy | Get Alert |
The latest price target for TG Therapeutics (NASDAQ: TGTX) was reported by HC Wainwright & Co. on May 2, 2024. The analyst firm set a price target for $49.00 expecting TGTX to rise to within 12 months (a possible 196.25% upside). 25 analyst firms have reported ratings in the last year.
The latest analyst rating for TG Therapeutics (NASDAQ: TGTX) was provided by HC Wainwright & Co., and TG Therapeutics maintained their buy rating.
The last upgrade for TG Therapeutics Inc happened on August 2, 2023 when Goldman Sachs raised their price target to $12. Goldman Sachs previously had a sell for TG Therapeutics Inc.
The last downgrade for TG Therapeutics Inc happened on November 15, 2021 when Goldman Sachs changed their price target from $33 to $26 for TG Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TG Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TG Therapeutics was filed on May 2, 2024 so you should expect the next rating to be made available sometime around May 2, 2025.
While ratings are subjective and will change, the latest TG Therapeutics (TGTX) rating was a maintained with a price target of $45.00 to $49.00. The current price TG Therapeutics (TGTX) is trading at is $16.54, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.